The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Prostate Cancer Incidence and PSA Testing Patterns in Relation to USPSTF Screening Recommendations
Abstract
IMPORTANCE: Prostate cancer incidence in men 75 years and older substantially decreased following the 2008 US Preventive Services Task Force (USPSTF) recommendation against prostate-specific antigen (PSA)-based screening for this age group. It is unknown whether incidence has changed since the USPSTF recommendation against screening for all men in May 2012. OBJECTIVE: To examine recent changes in stage-specific prostate cancer incidence and PSA screening rates following the 2008 and 2012 USPSTF recommendations. DESIGN AND SETTINGS: Ecologic study of age-standardized prostate cancer incidence (newly diagnosed cases/100,000 men aged ≥50 years) by stage from 2005 through 2012 using data from 18 population-based Surveillance, Epidemiology, and End Results (SEER) registries and PSA screening rate in the past year among men 50 years and older without a history of prostate cancer who responded to the 2005 (n = 4580), 2008 (n = 3476), 2010 (n = 4157), and 2013 (n = 6172) National Health Interview Survey (NHIS). EXPOSURES: The USPSTF recommendations to omit PSA-based screening for average-risk men. MAIN OUTCOMES AND MEASURES: Prostate cancer incidence and incidence ratios (IRs) comparing consecutive years from 2005 through 2012 by age (≥50, 50-74, and ≥75 years) and SEER summary stage categorized as local/regional or distant and PSA screening rate and rate ratios (SRRs) comparing successive survey years by age. RESULTS: Prostate cancer incidence per 100,000 in men 50 years and older (N = 446,009 in SEER areas) was 534.9 in 2005, 540.8 in 2008, 505.0 in 2010, and 416.2 in 2012; rates began decreasing in 2008 and the largest decrease occurred between 2011 and 2012, from 498.3 (99% CI, 492.8-503.9) to 416.2 (99% CI, 411.2-421.2). The number of men 50 years and older diagnosed with prostate cancer nationwide declined by 33,519, from 213,562 men in 2011 to 180,043 men in 2012. Declines in incidence since 2008 were confined to local/regional-stage disease and were similar across age and race/ethnicity groups. The percentage of men 50 years and older reporting PSA screening in the past 12 months was 36.9% in 2005, 40.6% in 2008, 37.8% in 2010, and 30.8% in 2013. In relative terms, screening rates increased by 10% (SRR, 1.10; 99% CI, 1.01-1.21) between 2005 and 2008 and then decreased by 18% (SRR, 0.82; 99% CI, 0.75-0.89) between 2010 and 2013. Similar screening patterns were found in age subgroups 50 to 74 years and 75 years and older. CONCLUSIONS AND RELEVANCE: Both the incidence of early-stage prostate cancer and rates of PSA screening have declined and coincide with 2012 USPSTF recommendation to omit PSA screening from routine primary care for men. Longer follow-up is needed to see whether these decreases are associated with trends in mortality.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Screening and Prostate-Cancer Mortality in a Randomized European Study
Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L. J., Ciatto, S., Nelen, V., Kwiatkowski, M., Lujan, M., Lilja, H., Zappa, M., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810084 · Cited by 4,014
Mortality Results from a Randomized Prostate-Cancer Screening Trial
Andriole, G. L., Crawford, E. D., Grubb, R. L., Buys, S. S., Chia, D., Church, T. R., Fouad, M. N., Gelmann, E. P., Kvale, P. A., Reding, D. J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0810696 · Cited by 2,906
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
Moyer, V. A., & on behalf of the U.S. Preventive Services Task Force* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-157-2-201207170-00459 · Cited by 2,522
Sathianathen, N. (2021) · 50 Studies Every Urologist Should Know · doi:10.1093/med/9780190655341.003.0002 · Cited by 2,080
Early Detection of Prostate Cancer: AUA Guideline
Carter, H. B., Albertsen, P. C., Barry, M. J., Etzioni, R., Freedland, S. J., Greene, K. L., Holmberg, L., Kantoff, P., Konety, B. R., Murad, M. H., et al. (2013) · Journal of Urology · doi:10.1016/j.juro.2013.04.119 · Cited by 1,242
Effect of Dutasteride on the Risk of Prostate Cancer
Andriole, G. L., Bostwick, D. G., Brawley, O. W., Gomella, L. G., Marberger, M., Montorsi, F., Pettaway, C. A., Tammela, T. L., Teloken, C., Tindall, D. J., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa0908127 · Cited by 1,152
Self-citationThe Decrease in Breast-Cancer Incidence in 2003 in the United States
Ravdin, P. M., Cronin, K. A., Howlader, N., Berg, C. D., Chlebowski, R. T., Feuer, E. J., Edwards, B. K., & Berry, D. A. (2007) · New England Journal of Medicine · doi:10.1056/nejmsr070105 · Cited by 982
American Cancer Society Guideline for the Early Detection of Prostate Cancer: Update 2010
Wolf, A. M. D., Wender, R. C., Etzioni, R. B., Thompson, I. M., D'Amico, A. V., Volk, R. J., Brooks, D. D., Dash, C., Guessous, I., Andrews, K., et al. (2010) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20066 · Cited by 965
Draisma, G., Etzioni, R., Tsodikov, A., Mariotto, A., Wever, E., Gulati, R., Feuer, E., & de Koning, H. (2009) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djp001 · Cited by 796
The Role of Increasing Detection in the Rising Incidence of Prostate Cancer
Potosky, A. L. (1995) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1995.03520310046028 · Cited by 674
Efficient interval estimation for age-adjusted cancer rates
Tiwari, R. C., Clegg, L. X., & Zou, Z. (2006) · Statistical Methods in Medical Research · doi:10.1177/0962280206070621 · Cited by 566
Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement
U.S. Preventive Services Task Force* (2008) · Annals of Internal Medicine · doi:10.7326/0003-4819-149-3-200808050-00008 · Cited by 505
Accuracy of Self-Reported Cancer-Screening Histories: A Meta-analysis
Rauscher, G. H., Johnson, T. P., Cho, Y. I., & Walk, J. A. (2008) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-07-2629 · Cited by 487
Estimating Model-Adjusted Risks, Risk Differences, and Risk Ratios From Complex Survey Data
Bieler, G. S., Brown, G. G., Williams, R. L., & Brogan, D. J. (2010) · American Journal of Epidemiology · doi:10.1093/aje/kwp440 · Cited by 460
Cohen, R. A., & Martinez, M. E. (2009) · PsycEXTRA Dataset · doi:10.1037/e565212009-001 · Cited by 412
Impact of Reporting Delay and Reporting Error on Cancer Incidence Rates and Trends
Clegg, L. X. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.20.1537 · Cited by 278
The Impact of Informed Consent on Patient Interest in Prostate-Specific Antigen Screening
Wolf, A. M. D. (1996) · Archives of Internal Medicine · doi:10.1001/archinte.156.12.1333 · Cited by 216
Drazer, M. W., Huo, D., & Eggener, S. E. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2015.61.6532 · Cited by 194
Loehrer, P. J. (2008) · Yearbook of Oncology · doi:10.1016/s1040-1741(08)79015-8 · Cited by 165
Barocas, D. A., Mallin, K., Graves, A. J., Penson, D. F., Palis, B. E., Winchester, D. P., & Chang, S. S. (2015) · The Journal of Urology · doi:10.1016/j.juro.2015.06.075 · Cited by 126
Prostate-Cancer Screening — What the U.S. Preventive Services Task Force Left Out
Brett, A. S., & Ablin, R. J. (2011) · New England Journal of Medicine · doi:10.1056/nejmp1112191 · Cited by 73
One Man at a Time — Resolving the PSA Controversy
McNaughton‐Collins, M., & Barry, M. J. (2011) · New England Journal of Medicine · doi:10.1056/nejmp1111894 · Cited by 73
Prabhu, V., Lee, T., Loeb, S., Holmes, J. H., Gold, H. T., Lepor, H., Penson, D. F., & Makarov, D. V. (2014) · British Journal of Urology · doi:10.1111/bju.12748 · Cited by 44
Cited by
Siegel, R. L., Miller, K. D., Fuchs, H. E., & Jemal, A. (2022) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21708 · Cited by 17,196
Self-citationSiegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Self-citationSiegel, R. L., Miller, K. D., Wagle, N. S., & Jemal, A. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21763 · Cited by 16,303
Self-citationSiegel, R. L., Giaquinto, A. N., & Jemal, A. (2024) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21820 · Cited by 9,533
Self-citationSiegel, R. L., Kratzer, T. B., Giaquinto, A. N., Sung, H., & Jemal, A. (2025) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21871 · Cited by 3,060
Self-citation
Metadata
- Authors
- Jemal, A., Fedewa, S. A., Ma, J., Siegel, R., Lin, C. C., Brawley, O., & Ward, E. M.
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2015-11-17
- Volume
- 314
- Issue
- 19
- Pages
- 2054
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W2175023894
- Cited by
- 469
- References
- 23
- FWCI
- 54.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.